结核病合并抗-HCV阳性患者临床诊疗的常见问题

詹淑华; 陈青; 马世武

doi:10.3969/j.issn.1001-5256.2018.12.036

结核病合并抗-HCV阳性患者临床诊疗的常见问题

DOI: 10.3969/j.issn.1001-5256.2018.12.036

1. 昆明医科大学成都军区昆明总医院临床学院
2. 成都军区昆明总医院感染科

基金项目:

云南省中青年学术技术带头人项目(第十八批)；

详细信息

中图分类号: R52;R512.63
计量
- 文章访问数: 1003
- HTML全文浏览量: 19
- PDF下载量: 324
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Clinical issues in the diagnosis and treatment of tuberculosis patients with positive antibody to hepatitis C virus

Research funding:

摘要

摘要: 临床上经常会遇到结核合并抗-HCV阳性患者（TB-HCV）,其中也包含了结核患者合并HCV现症感染者,这给临床管理和诊治带来了一定的困难。介绍了国内外TB-HCV流行率情况,并逐步分析了在TB-HCV患者诊治过程中可能发生的药物相互作用、药物性肝损伤、HCV再激活和TB再激活等系列问题。认为在诊疗TB-HCV患者时应该加强管理,选择恰当的治疗方案。
- 结核 /
- 肝炎病毒属 /
- 药物相互作用 /
- 药物性肝损伤 /
- 病毒激活 /
- 综述
Abstract: Tuberculosis patients with positive antibody to hepatitis C virus (TB-HCV patients) are often seen in clinical practice, and these TB-HCV patients include those with HCV infection. That makes the clinical management and diagnosis/treatment of TB-HCV difficult. This article introduces the prevalence of TB-HCV around the world, and analyzes the potential issues in the diagnosis and treatment of TB-HCV patients, such as drug-drug interactions, drug-induced liver injury, HCV reactivation, and TB reactivation. Through this review, it is recommended that the management should be strengthened and the appropriate therapeutic regimen should be selected in the diagnosis and treatment of TB-HCV patients.
- tuberculosis /
- hepacivirus /
- drug-drug interactions /
- drug-induced liver injury /
- virus activation /
- review

HTML全文

参考文献(44)

[1] World Health Organization. Global Tuberculosis Report 2017.[EB/OL]. http://www. who. int/tb/publications/global_report/en/.

[2] National Bureau of Statistics. Reports on morbidity and mortality of statutory category A and B infectious diseases[EB/OL]. http://data. stats. gov. cn/easyquery. htm? cn=C01. (in Chinese) 国家统计局.甲乙类法定传染病发病人数和死亡人数报告[EB/OL]. http://data. stats. gov. cn/easyquery. htm? cn=C01.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版[J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[4] MO P, ZHU Q, TETER C, et al. Prevalence drug-induced hepatotoxicity and mortality among patients multi-infected with HIV tuberculosis and hepatitis virus[J]. Int J Infect Dis, 2014, 28:95-100.

[5] SHEN ER, ZHANG H, MA SW. Four clinical inconsistencies in tuberculosis patients coinfected with hepatitis B virus[J]. Chin Hepatol, 2016, 21 (11) :990-994. (in Chinese) 申恩瑞, 张慧, 马世武.结核菌和乙型肝炎病毒合并感染带来的四个临床矛盾[J].肝脏, 2016, 21 (11) :990-994.

[6] LOMTADZE N, KUPREISHVILI L, ALAKAIA A, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis druginduced hepatotoxicity among patients with pulmonary tuberculosis[J]. PLo S One, 2013, 8 (12) :1-11.

[7] LU FF, TAN Y, FU ZX, et al. Rv2645 from mycobacterium tuberculosis RD13 region promoters ISG15 expression and overexpression of ISG15 enhances HCV replication in vitro[J]. Chin J Virol, 2017, 33 (3) :372-379. (in Chinese) 卢芳芳, 谭杨, 付忠晓, 等.结核分枝杆菌RV2645刺激ISG15的表达上升促进体外丙型肝炎病毒的增殖[J].病毒学报, 2017, 33 (3) :372-379.

[8] SIRINAK C, KITTIKRAISAK W, PINJEESEKIKUL D, et al. Viral hepatitis and HIV-associated tuberculosis:Risk factors and TB treatment outcomes in Thailand[J]. BMC Public Health, 2008, 8 (1) :245-245.

[9] REIS NR, LOPES CL, TELES SA, et al. Hepatitis C virus infection in patients with tuberculosis in Central Brazil[J]. Int J Tuberc Lung Dis, 2011, 15 (10) :1397-1402.

[10] BUSHNELL G, STENNIS NL, DROBNIK AM, et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000-2010[J]. Epidemiol Infect, 2015, 143 (9) :1972-1981.

[11] GU JY, ERXIDING MMT, XIANG Y, et al. The analysis of distribution and associated liver damage in patient with tuberculosis and underlying hepatitis C[J]. Chin J Dis Control Prev, 2015, 19 (2) :119-122. (in Chinese) 顾佳怡, 尔西丁·买买提, 向阳, 等.肺结核病人中丙型肝炎分布特征及其与肝功能损害的关联性分析[J].中华疾病控制杂志, 2015, 19 (2) :119-122.

[12] WANG JY, LIU CH, HU FC, et al. Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load[J]. J Infect, 2011, 62 (6) :448-455.

[13] WU PH, LIN YT, HSIEH KP, et al. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease a nationwide population-based study[J]. Medicine, 2015, 94 (33) :e1328.

[14] KUNIHOLM MH, MARK J, ALADASHVILI M, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients[J]. Int J Infect Dis, 2008, 12 (1) :51-56.

[15] LIU D, LIU Y, HUANG FX, et al. Hepatitis C antibody test results:Analysis of 2 947 patients with tuberculosis (TB) [J]. J Pathog Biol, 2012, 7 (11) :insert 2-3. (in Chinese) 刘丹, 刘艳, 黄费湘, 等. 2947例结核 (TB) 患者丙型肝炎病毒抗体检测结果分析[J].中国病原生物学杂志, 2012, 7 (11) :附页2-3.

[16] CAMPO M, SHRESTHA A, ORENO E, et al. Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA[J]. Epidemiol Infect, 2014, 142 (7) :1459-1466.

[17] CHENG XZ, LI WB, ZHANG H, et al. Investigation in tuberculosis patients combined with hepatitis or other infectious diseases[J].Henan J Prevent Med, 2015, 26 (1) :42-46. (in Chinese) 程新征, 李卫彬, 张辉, 等.肺结核患者合并肝炎等传染性疾病调查分析[J].河南预防医学杂志, 2015, 26 (1) :42-46.

[18] NOOREDINVAND HA, CONNELL DW, ASGHEDDI M, et al.Viral hepatitis prevalence in patients with active and latent tuberculosis[J]. World J Gastroenterol, 2015, 21 (29) :8920-8926.

[19] MERZA MA, HAJI SM, ALSHARAFANI AM, et al. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan:Are HBs Ag and anti-HCV prerequisite screening parameters in tuberculosis control program[J]. Int J Mycobacteriol, 2016, 5 (3) :313-317.

[20] COSTI C, GRANDI T, HALON ML, et al. Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil[J]. Mem Inst Oswaldo Cruz, 2017, 112 (4) :255-259.

[21] LI JL, SHANG J, NING HB. Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34 (2) :242-245. (in Chinese) 李俊利, 尚佳, 宁会彬.直接抗病毒药物时代特殊人群HCV感染的管理和治疗[J].临床肝胆病杂志, 2018, 34 (2) :242-245.

[22] KIRBY BJ, SYMONDS WT, KEARNEY BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B poly-merase inhibitor sofosbuvir[J]. Clin Pharmacokinet, 2015, 54 (7) :677-690.

[23] MARRA F, GERMAN P, PANG P, et al. Drug-drug interaction profile, including HIV ART, of the HCV fixed-dose combination tablet ledipasvir/sofosbuvir[J]. Hiv Med, 2015, 16:35-35.

[24] SEKAR V, VERLOES R, MEYVISCH P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers[J]. J Hepatol, 2010, 52 (Suppl 1) :416-416.

[25] ZHOU SN, ZHANG M. Metabolism and drug interactions of direct-acting antiviral agents for hepatitis C[J]. Infect Dis Inf, 2016, 29 (2) :121-125. (in Chinese) 周双男, 张敏.丙型肝炎直接抗病毒药物的代谢及药物相互作用[J].传染病信息, 2016, 29 (2) :121-125.

[26] HEP Drug Interactions, 2018[EB/OL]. http://hep-druginteractions. org.

[27] Up To Data websute[EB/OL]. http://www. uptodate. com.

[28] XUE XP, GUO XL, WANG LP. Clinical research on combined therapy of interferon and ribavirin for hepatitis C cirrhosis[J]. Int J Virol, 2016, 23 (2) :127-129. (in Chinese) 薛小萍, 郭晓莉, 王丽萍.干扰素联合利巴韦林治疗丙肝肝硬化的临床研究[J].国际病毒学杂志, 2016, 23 (2) :127-129.

[29] MATSUOKA S, FUJIKAWA H, HASEGAWA H, et al. Onset of tuberculosis from a pulmonary latent tuberculosis infection during antiviral triple therapy for chronic hepatitis C[J]. Intern Med, 2016, 55 (15) :2011-2017.

[30] ABUTIDZE A, BOLOKADZ N, CHKHARTISHVILI N, et al. Incidence of tuberculosis among HIV/HCV coinfected patients receiving hepatitis C treatment with pegylated interferon and ribavirin in Georgia[J]. Georgian Med News, 2016, (252) :10-15.

[31] LIN SY, CHEN TC, LU PL, et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy:A population-based cohort study in Taiwan[J].BMC Infect Dis, 2014, 14 (1) :705.

[32] BABUDIERI S, SODDU A, MURINO M, et al. Tuberculosis screening before anti-hepatitis C virus therapy in prisons[J]. Emerg Infect Dis, 2012, 18 (4) :689-691.

[33] SABBATANI S, MANFREDI R, MARINACCI G, et al. Reactivation of severe acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis[J]. Scand Infect Dis, 2006, 38 (3) :205-208.

[34] TELESCA C, ANGELICO M, PICCOLO P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant[J]. J Infect, 2007, 54 (4) :223-226.

[35] SENOUSY B, BELAL S, DRAGANOY P, et al. Hepatotoxic effects of therapies for tuberculosis[J]. Nat Rev Gastroenterol Hepatol, 2010, 7 (10) :543-546.

[36] BOUAZZI O, HAMMI S, BOURKADI J, et al. First line anti-tuberculosis induced hepatotoxicity:Incidence and risk factors[J].Pan Afr Med, 2016, 16 (25) :167.

[37] Chinese Society for Tuberculosis, Chinese Medical Association. Expert recommendations on diagnosis and treatment of anti-tuberculosis liver injury[J]. Chin J Tuberc Respir Dis, 2013, 36 (10) :732-736. (in Chinese) 中华医学会结核病学分会.抗结核药所致药物性肝损伤诊断与处理专家建议[J].中华结核和呼吸杂志, 2013, 36 (10) :732-736.

[38] ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21, 789 patients[J]. Eur J Gastroenterol Hepatol, 2013, 25 (7) :825-829.

[39] SHANG P, XIA Y, LIU F, et al. Incidence clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China[J]. PLo S One, 2011, 6 (7) :e21836.

[40] KIM WS, LEE SS, LEE CM, et al. Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury[J]. BMC Infect Dis, 2016, 16 (1) :50.

[41] TSAI MC, LIN MC, HUNG CH. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis[J]. Formos Med Assoc, 2009, 108 (9) :746-750.

[42] WU Z, HUO N, LI J, et al. Advances in the diagnosis and therapy of hepatitis C virus reactivation[J]. Chin J Pract Intern Med, 2016, 36 (3) :212-215. (in Chinese) 吴朝, 霍娜, 李俊, 等.丙型肝炎病毒再激活诊疗进展[J].中国实用内科杂志, 2016, 36 (3) :212-215.

[43] CIESEK S, STEINMANN E, IKEN M, et al. GIucocorticosteroid increase cell entry by hepatitis C virus[J]. Gastroenterology, 2010, 138 (5) :1875-l884.

[44] CHEN MH, CHEN MH, TSAI CY, et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy[J]. Lupus, 2015, 24 (10) :1029-1036.

施引文献

资源附件(0)

访问统计